DDrare: Database of Drug Development for Rare Diseases

Emtricitabine (DrugBank: Emtricitabine)

4 diseases

ID	Disease name (Link within this page)	Number of trials
25	Progressive multifocal leukoencephalopathy	1
93	Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)]	1
265	Lipodystrophy	1
325	Hereditary autoinflammatory syndrome	1

25. Progressive multifocal leukoencephalopathy [ 23 clinical trials, 33 drugs, (DrugBank: 20 drugs), 7 drug target genes, 36 drug target pathways]

Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 23 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00120367 (ClinicalTrials.gov)	April 2005	11/7/2005	Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)	Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial	Leukoencephalopathy, Progressive Multifocal;HIV Infections	Drug: Enfuvirtide;Drug: Tenofovir-Emtricitabine	French National Agency for Research on AIDS and Viral Hepatitis	Hoffmann-La Roche;Gilead Sciences	Completed	18 Years	N/A	Both	30	Phase 2	France

93. Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] [ 230 clinical trials, 215 drugs, (DrugBank: 51 drugs), 34 drug target genes, 107 drug target pathways]

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 230 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03954327 (ClinicalTrials.gov)	September 2020	7/5/2019	Combination Antiretroviral Therapy (cART) for PBC	Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)	Primary Biliary Cholangitis	Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF);Drug: Raltegravir;Drug: Placebo Oral Capsule [CEBOCAP]	University of Alberta	Merck Sharp & Dohme Corp.	Not yet recruiting	18 Years	N/A	All	60	Phase 2	Canada

265. Lipodystrophy [ 109 clinical trials, 164 drugs, (DrugBank: 59 drugs), 26 drug target genes, 94 drug target pathways]

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 109 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-004021-26-GB (EUCTR)	06/10/2005	05/09/2005	Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. - Mitochondrial DNA Study	Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. - Mitochondrial DNA Study	HIV		University Hospital Birmingham	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 4	United Kingdom

325. Hereditary autoinflammatory syndrome [ 6 clinical trials, 10 drugs, (DrugBank: 6 drugs), 2 drug target genes, 33 drug target pathways]

Searched query = "Hereditary autoinflammatory syndrome", "NLRC4 abnormality", "Adenosine deaminase 2 deficiency", "ADA2 deficiency", "Aicardi-Goutieres syndrome", "A20 haploinsufficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 6 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03304717 (ClinicalTrials.gov)	January 2021	4/8/2017	Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome	Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome	Aicardi Goutières Syndrome	Drug: Tenofovir (TDF) and Emtricitabine (FTC);Other: Placebo	Children's Hospital of Philadelphia	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Human Genome Research Institute (NHGRI);Gilead Sciences;Emerson Resources;National Institutes of Health (NIH)	Not yet recruiting	2 Years	18 Years	All	34	Phase 1;Phase 2	United States